tiprankstipranks
Advertisement
Advertisement

TARA Stock Latest News

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch
Company AnnouncementsProtara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch
2d ago
TARA
Protara: Strategic Trial Redesign and Strong TARA-002 Profile Support Buy Rating with Unchanged $27 Price Target
PremiumRatings
Protara: Strategic Trial Redesign and Strong TARA-002 Profile Support Buy Rating with Unchanged $27 Price Target
11d ago
TARA
Protara Therapeutics: Advancing Pipeline and Strong Cash Runway Underpin Boris Peaker’s Buy Rating and $25 Price Target
PremiumRatings
Protara Therapeutics: Advancing Pipeline and Strong Cash Runway Underpin Boris Peaker’s Buy Rating and $25 Price Target
12d ago
TARA
Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26
PremiumRatings
Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26
12d ago
TARA
Protara Therapeutics reports Q2 EPS (36c), consensus (31c)
PremiumThe Fly
Protara Therapeutics reports Q2 EPS (36c), consensus (31c)
12d ago
TARA
Is TARA a Buy, Before Earnings?
PremiumPre-EarningsIs TARA a Buy, Before Earnings?
27d ago
TARA
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up
Premium
Weekend Updates
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up
2M ago
ABEO
CBRS
Protara Therapeutics Announces Key Medical Leadership Transition
Premium
Company Announcements
Protara Therapeutics Announces Key Medical Leadership Transition
2M ago
8K
TARA
Protara Therapeutics Stockholders Approve Governance and Share Increases
PremiumCompany Announcements
Protara Therapeutics Stockholders Approve Governance and Share Increases
2M ago
8K
TARA
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
PremiumThe Fly
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
3M ago
TARA
Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
PremiumRatings
Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
3M ago
TARA
Unusually active option classes on open May 15th
PremiumThe Fly
Unusually active option classes on open May 15th
3M ago
AGQ
CSX
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
PremiumThe FlyProtara announces updated 12-month data from Cohort A of ADVANCED-2 trial
3M ago
TARA
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
Premium
The Fly
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
3M ago
TARA
Protara Therapeutics files $300M mixed securities shelf
Premium
The Fly
Protara Therapeutics files $300M mixed securities shelf
3M ago
TARA
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
PremiumThe Fly
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
3M ago
TARA
JPMorgan healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
5M ago
CGON
TARA
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
PremiumCompany Announcements
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
5M ago
8K
TARA
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
PremiumRatings
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
5M ago
TARA
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
PremiumRatingsProtara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
6M ago
TARA
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
Premium
The Fly
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
6M ago
TARA
Protara Therapeutics sees cash runway into 2028
Premium
The Fly
Protara Therapeutics sees cash runway into 2028
6M ago
TARA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >